Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10803361 | 0.79 | CES2 (0.40) | HPGD | |
| SCHEMBL2916902 | 0.79 | HPGD (0.46) | POLBHPGDNPC1RAB9ALMNA | |
| SCHEMBL23480530 | 0.77 | KEAP1 (0.59) | — | |
| SCHEMBL30313288 | 0.77 | KEAP1 (0.59) | — | |
| SCHEMBL8348114 | 0.75 | TRPA1 (0.42) | HPGDTSHRNPC1RAB9ASMN1; SMN2 | |
| Methylene Chloride SCHEMBL4572767 | 0.75 | HPGD (0.43) | HPGDNPC1RAB9ALMNAGAA | |
| SCHEMBL4643747 | 0.74 | TSHR (0.55) | POLBHPGDMAPTTSHRNPC1 | |
| SCHEMBL8055152 | 0.73 | POLB (0.55) | POLBAPEX1HPGDMAPTTSHR | |
| SCHEMBL16590415 | 0.71 | KCNQ3 (0.43) | TSHR | |
| SCHEMBL3820327 | 0.71 | POLB (0.53) | POLBAPEX1HPGDMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247452-B2 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-08-21 | — | — | US | disclosed |
| EP-1654224-B1 | SUBSTITUTED BENZOYLUREIDO-O-BENZOYLAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-02-09 | — | — | EP | disclosed |
| EP-1523475-B1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-12-23 | — | — | EP | disclosed |
| EP-1590322-B1 | CARBONYL-AMINO SUBSTITUTED ACYL PHENYL UREA DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-09-23 | — | — | EP | disclosed |
| EP-1523471-B1 | UREA-SUBSTITUTED AND URETHANE-SUBSTITUTED ACYLUREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-1597247-B1 | SUBSTITUTED 3-(BENZOYLUREIDO)-THIOPHENE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-7378440-B2 | Substituted benzoylureido-o-benzoylamides, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-27 | — | — | US | disclosed |
| US-20080033042-A1 | UREA-AND URETHANE-SUBSTITUTED ACYLUREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| US-7262220-B2 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| WO-2004007437-A9 | UREA-SUBSTITUTED AND URETHANE-SUBSTITUTED ACYLUREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| US-20050014822-A1 | Type 2 diabetes; such as n-{3-[3-(2-Chloro-4,5-difluorobenzoyl)ureido]-4-trifluoromethoxyphenyl}acetamide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20040198742-A1 | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| WO-2004072060-A1 | SUBSTITUTED 3-(BENZOYLUREIDO)-THIOPHENE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004065356-A1 | CARBONYL-AMINO SUBSTITUTED ACYL PHENYL UREA DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | US | disclosed |
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA AG (DE) | 2004-05-27 | — | — | US | disclosed |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| WO-2004007455-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007437-A1 | UREA-SUBSTITUTED AND URETHANE-SUBSTITUTED ACYLUREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003104188-A1 | N-BENZOYLUREIDOCINNAMATE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | SLC5A1, NQO1, SLC5A2 | POLB 2502/4885APEX1 382/4885HPGD 76/4885 |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | UGP2, UGDH, UGT1A1 | POLB 2016/4885APEX1 577/4885HPGD 996/4885 |
| US-20080033042-A1 | UREA-AND URETHANE-SUBSTITUTED ACYLUREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE | UGP2, UGDH, UMPS | POLB 2082/4885APEX1 826/4885HPGD 918/4885 |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SLC5A2, CYP1B1, CYP2C19 | POLB 1626/4885APEX1 2721/4885HPGD 482/4885 |
| US-20050014822-A1 | Type 2 diabetes; such as n-{3-[3-(2-Chloro-4,5-difluorobenzoyl)ureido]-4-trifluoromethoxyphenyl}acetamide | SLC5A2, NFE2L2, SLC5A1 | POLB 3823/4885APEX1 3989/4885HPGD 656/4885 |
| US-20040198742-A1 | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use | SLC5A2, TXNRD2, SLC5A1 | POLB 2522/4885APEX1 447/4885HPGD 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.